Basel Medical Group Ltd (BMGL)

BMGL · BiotechSign Pipeline

Pipeline Overview

Therapeutic Focus: Biotech / Pharmasrc

Signal Snapshot

Clinical Trials (ClinicalTrials.gov aggregate)

Catalyst Records

Publications on Record

ClinicalTrials.gov aggregate as of 2026-09-29. Source

Recent Publications

Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. — Ophthalmol Ther (2026) PMID 42771326
A consensus-based guideline for personalized bacteriophage therapy. — Nat Med (2026) PMID 42768217

5 total publications tracked — view all on BiotechSign

Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Basel Medical Group Ltd.

Full BMGL Data Sign Up Free

Primary Sources

Company identity
Therapeutic indication
Clinical trial aggregate
Publication 42771326
Publication 42768217
Publication 42752431
Publication 42739115
Publication 42738410

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.